Purpose: To examine the efficacy of low-dose hCG using a GnRH antagonist protocol.
Methods: Prospective randomized study was performed at the Kyono Ladies Clinic. One hundred ninety-two women (<40 –years old, <3 previous cycles) were randomly assigned to GnRH agonist (buserelin) long protocol (LP, n = 66), GnRH antagonist (cetrorelix) with no low-dose hCG protocol (NhCGP, n = 63), or GnRH antagonist with low-dose hCG protocol (hCGP, n = 63).
Results: The hCGP was associated with reduced total amounts of FSH, increased oocyte maturation rate, high-quality day 3 embryos rate, and number of frozen embryos. Ovarian hyperstimulation syndrome (OHSS) tended to be lower in the GnRH antagonist protocol. Pregnancy and implantation rates did not differ significantly between study groups.
Conclusions: Daily low-dose hCG supplementation in the late follicular phase could improve the outcome in FSH based-GnRH antagonist protocol. This protocol, however, does require further modifications, including determination of the optimal doses for hCG and gonadotropin pretreatment.
Similar content being viewed by others
REFERENCES
Alvano C, Felberbaum RE, Smitz J, Riethmuller-Winzen H, Engel J, Diedrich K, Devroey P: Ovarian stimulation with hMG: Results of a prospective randomized phase III European study comparing the luteinizing hormone-releasing hormone (LHRH)-antagonist cetrorelix and the LHRH-agonist buserelin. European Cetrorelix Study Group. Hum Reprod 2000;15:526–531
Ludwig M, Katalinic A, Diedrich K: Use of GnRH antagonists in ovarian stimulation for assisted reproductive technologies compared to the long protocol. Meta analysis. Arch Gynecol Obstet 2001;265:175–182
Al-Inary H, Aboulghar H: GnRH antagonist in assisted reproduction: A Cochran review. Hum Reprod 2002;17:874–885
Zeleznik AJ, Hillier SG: The role of gonadotropins in the selection of the preovulatory follicle. Clin Obstet Gynecol 1984;27:927–940
Filicori M, Cognigni GE, Taraborrelli D, Spettoli D, Ciampaglia W, de Fatis CT, Pocognoli P: Luteinizing Hormone Activity Supplementation Enhances Follicle-Stimulating Hormone Efficacy and Improves Ovulation Induction Outcome. J Clin Endocrinol Metab 1999;84:2659–2663
Filicori M, Cognigni GE, Tabarelli C, Pocognoli P, Taraborrelli S, Spettoli D, Ciampaglia W: Stimulation and growth of antral ovarian follicles by selective LH activity administration in women. J Clin Endocrinol Metab 2002;87:1156–1161
Filicori M, Cognigni GE, Pocognoli P, Tabarelli C, Ferlini F, Perri T, Parmegiani L: Comparison of controlled ovarian stimulation with human menopausal gonadotropin or recombinant follicle stimulating hormone. Fertil Steril 2003;80:390–397
Filicori M, Cognigni GE, Gamberini E, Parmegiani L, Troilo E, Roset B: Efficacy of low-dose human chorionic gonadotropin alone to complete controlled ovarian stimulation. Fertil Steril 2005;84:394–401
Filicori M, Fazleabas AT, Huhtaniemi I, Licht P, Rao ChV, Tesarik J, Zygmunt M: Novel concepts of human chorionic gonadotropin: Reproductive system interactions and potential in the management of infertility. Fertil Steril 2005;84:275–284
Golan A, Ron-EI R, Herman A, Weinraub Z, Soffer Y, Capsi E: Ovarian hyperstimulation syndrome: An update review. Obstet Gynecol Surv 1989;44:430–440
Hillier SG: Current concepts of the roles of follicle stimulating hormone and luteinizing hormone in folliculogenesis. Hum Reprod 1994;9:188–191
Chappel S, Howles C: Re-evaluation of the roles of luteinizing hormone and follicle-stimulating hormone in the ovulatory process. Hum Reprod 1991;6:1206–1212
Fleming R, Chung CC, Yates RWS, Coutts JRT: Purified urinary follicle stimulating hormone induces different hormone profiles compared with menotrophins, dependent upon the route of administration and endogenous luteinizing hormone activity. Hum Reprod 1996;11:1854–1858
Gordon UD, Harrison RF, Fawzy M, Hennelly B, Gordon AC: A randomized prospective assessor-blind evaluation of luteinizing hormone dosage and in vitro fertilization outcome. Fertil Steril 2001;75:324–331
Ferraretti AP, Gianaroli L, Magli MC, D’angelo A, Farfali V, Montanaro N: Exogenous luteinzing hormone in controlled ovarian hyperstimulation for assisted reproduction techniques. Fertil Steril 2004;82:1521–1526
Rao CV: Multiple novel roles of luteinizing hormone. Fertil Steril 2001;76:1097–1100
Semesh M: Actions of gonadotrophins on the uterus. Reproduction 2001;121:835–842
Tesarik J, Mendoza JK: Effects of exogenous LH administration during ovarian stimulation of pituitary down-regulated young oocyte donors on oocyte yield and developmental competence. Hum Reprod 2002;17:3129–3137
Tesaric J, Hazout A, Mendoza C: Luteinizing hormone affects uterine receptivity independently of ovarian function. Reprod Biomed Online 2003;7:59–64
Garirelix ose Finding Study Group: A double-blind, randomized, dose-finding study to assess the efficacy of the gonadotrophin-releasing hormone antagonist ganirelix (Org 37462) to prevent premature luteinizing hormone surges in women undergoing ovarian stimulation with recombinant follicle stimulating hormone (Puregon®). Hum Reprod 1998;13:3023–3031
Kolibianakis EM, Albano C, Kahn J, Camus M, Touraye H, Van Steirteghem AC, Devroey P: Exposure to high levels of luteinizing hormone and estradiol in the early follicular phase of gonadotropin-releasing hormone antagonist cycles is associated with a reduced chance of pregnancy. Fertil Steril 2003;79:873–880
Stanger JD, Yovich JL: Reduced in-vitro fertilization of human oocytes from patients with raised basal luteinizing hormone levels during the follicular phase. Br J Obstet Gynecol 1985;92:385–393
Howles CM, Macnamee MC, Edwards RG, Goswamy R, Steptoe PC: Effect of high tonic levels of luteinizing hormone on outcome of in-vitro fertilization. Lancet 1986;2:521–522
Homburg R, Armar NA, Eshel A, Adams J, Jacobs HS: Influence of serum luteinizing hormone concentrations on ovulation, conception, and early pregnancy loss in polycystic ovary syndrome. Br Med J 1988;297:1024–1026
Serono Study No. 7313: Data on file, 1998, Geneva, Switzerland.
The European Recombinant Human LH Study Group: Recombinant human luteinizing hormone (LH) to support recombinant follicle stimulating hormone (FSH) -induced follicular development in LH-and FSH-deficient anovulatory women: A dose-finding study. J Clin Endocrinol Metab 1998;83:1507–1514
Marrs R, Meldrum D, Muasher S, Schoolkraft W, Werlin L, Kelly E: Randomized trial to compare the effect of recombinant human FSH (follitropin alfa) with or without recombinant human LH in women undergoing assisted reproduction treatment. Reprod BioMed Online 2003;8:175–182
Humaidan P, Bungum M, Bungum L, Anderson CY: Effect of recombinant LH supplementation in women undergoing assisted reproduction with GnRH agonist down-regulation and stimulation with recombinant FSH: An opening study. Reprod BioMed Online 2004;8:635–643
Stokman PG, de Leeuw R, van den Wijngaard HA, Kloosterboer HJ,Vemer HM, Sanders AL: Human chorionic gonadotropin in commercial human menopausal gonado-tropin preparations. Fertil Steril 1993;60:176–178
The European Recombinant LH study Group: Human recombinant luteinizing hormone is as effective as, but safer than, urinary human chorionic gonadotropin in inducing final follicular maturation and ovulation in in vitro fertilization procedures: Results of a multicenter double-blind study. J Clin Endocrinol Metab 2001;86:2607–2618
Sullivan M, Stewart-Akers A, Krasnow JS, Berga SL, Zeleznik AJ: Ovarian responses in women to recombinant follicle stimulating hormone and luteinizing hormone (LH): A role for LH in the final stages of follicular maturation. J Clin Endocrinol Metab 1999;84:228–232
Loumaye E, Engrand P, Shoham Z, Hillier SG, Baird DT on behalf of the recombinant LH study group. Clinical evidence of an LH ceiling effect induced by administration of recombinant human LH during the late follicular phase of stimulated cycles in World Health Organization type I ans type II anovulation. Hum Reprod 2003;18:314–322.
Takahashi K, Kurioka H, Ozaki T, Kanasaki H, Kohsaka M, Miyasaki K, Karino K: Increased prevalence of luteinizing hormone β-subunit variant in Japanese infertility patients. Hum Reprod 1998;13:3338–3344
Fanchin R, Salomon L, Castero-Branco A, Olivennes F, Frydman N, Frydman R: Luteal estradiol pre-treatment coordinates follicular growth during controlled Ovarian hyperstimulation with GnRH antagonists. Hum Reprod 2003;18:2698–2703
Fanchin R, Castelo A, Kadoch IJ, Hosny G, Bagirova M, Frydman R: Premenstrual administration of gonadotropin-releasing hormone antagonist coordinates early antral follicle sizes and sets up the basis for an innovative concept of controlled ovarian hyperstimulation. Fertil Steril 2004;81:1554–1559
ACKNOWLEDGMENT
The authors thank Mr. Nobuhide Ebina for the analysis of the data and statistical advice
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Koichi, K., Yukiko, N., Shima, K. et al. Efficacy of Low-Dose Human Chorionic Gonadotropin (hCG) in a GnRH Antagonist Protocol. J Assist Reprod Genet 23, 223–228 (2006). https://doi.org/10.1007/s10815-006-9036-2
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10815-006-9036-2